Our website is currently undergoing maintenance. Article records and full texts remain available. Submissions can be made through the Editorial Manager.
Tricalcium Phosphate Nanostructures Loaded with Bisphosphonate as Potential Anticancer Agents
M. Rahmanian, S.M. Naghib, A. Seyfoori, A.A. Zare, A.A. Zare, K. Majidzadeh-A, K. Majidzadeh-A, L. Farahmand, L. Farahmand
Abstract
Nanostructured calcium phosphate carriers are emerging as a bisphosphonate delivery system that has demonstrated inhibitory effects in preventing bone metastasis, thereby improving the treatment of breast cancer. In this research, the inhibitory effect of loaded zoledronic acid (ZA) in tricalcium phosphate nanostructures (TCPNs) synthesized with the co-precipitation method was investigated. The results of microstructural analysis indicated that the sintering temperature has a slight influence on the synthesized crystallite size. The sintered crystallite size of tricalcium phosphate (TCP) at 800 °C (β-TCP) and 1450 °C (α-TCP) was calculated to be in the nanoscale range. The inhibitory effect of TCPNs (with different phases) on cancer cell lines including MCF-7 (breast cancer) and G-292 (osteosarcoma cancer) was investigated. In vitro results confirmed that the TCPNs were able to inhibit the proliferation of breast cancer cells. Experimental results of MCF-7 cell culture after two days proved that the growth of the cancer cells was inhibited by about 61 % and 83 % after treatment with β-TCP and α-TCP, respectively. Bisphosphonate-loaded TCPNs had no toxicity according to MTT assay results, but did have an inhibitory effect on MCF-7 cancer cells. The time dependence of ZA drug release from α and β-TCP and its effect on MCF-7 and G-292 cell treatment was investigated. The results suggested that TCPNs are promising materials that could be developed for treating local bone and breast cancers.
Keywords
MCF-7, G-292, tricalcium phosphate, nanomedicine, inhibitory effect
Göller Verlag GmbH · info@goeller-verlag.de · Site Notice · Privacy · Terms